AskAt Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Private

  • Employees
  • 10

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 2

AskAt General Information

Description

Developer of drug discovery programs designed to develop new drugs based on an open collaboration network. The company provides various drugs, including cancer immunotherapeutic, pain remedies, dementia remedies, and autoimmune disease treatments, and the company licenses the created intellectual property to pharmaceutical companies and pharmaceutical development ventures, enabling healthcare professionals to improve their quality of life.

Contact Information

Website
www.askat-inc.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 4th Floor, Station Ai
  • 1-2-32 Tsurumai, Showa-ku
  • Nagoya, Aichi 466-0064
  • Japan
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Digital Health, Life Sciences, Oncology
Corporate Office
  • 4th Floor, Station Ai
  • 1-2-32 Tsurumai, Showa-ku
  • Nagoya, Aichi 466-0064
  • Japan

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

AskAt Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Secondary Transaction - Private Completed Generating Revenue
8. Later Stage VC 26-Feb-2021 Completed Generating Revenue
7. Later Stage VC 30-Nov-2020 Completed Generating Revenue
6. Later Stage VC 21-Oct-2020 Completed Generating Revenue
5. Early Stage VC 10-May-2017 Completed Generating Revenue
4. Early Stage VC 18-Mar-2016 Completed Generating Revenue
3. Early Stage VC 01-Jan-2016 Completed Startup
2. Early Stage VC 01-Aug-2015 Completed Startup
1. Seed Round 01-Jun-2015 Completed Startup
To view AskAt’s complete valuation and funding history, request access »

AskAt Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
A preferred
To view AskAt’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

AskAt Patents

  • 173

    Total Documents Applications and Grants

  • Total Patents Families

  • 125

    Granted

  • 11

    Pending

  • Expiring in next 12 mo

AskAt Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026142920-A2 Treating or preventing pain and/or inflammation and/or controlling pyrexia/fever with (s)-6-chloro-7-(1,1-dimethylethyl)-2-trifluoromethyl-2h-1-benzopyran-3-carboxylic acid or a salt thereof or a hydrate thereof Pending 27-Dec-2024
JP-2023544218-A 2-[3-({1-[2-(dimethylamino)ethyl]-2-(2,2-dimethylpropyl)-1h-1,3-benzodiazol-5-yl}sulfonyl)azetidine-1- stable salts and crystalline forms of yl]ethane-1-ol Active 12-Nov-2020
JP-7427309-B2 2-[3-({1-[2-(dimethylamino)ethyl]-2-(2,2-dimethylpropyl)-1h-1,3-benzodiazol-5-yl}sulfonyl)azetidine-1- stable salts and crystalline forms of yl]ethane-1-ol Active 12-Nov-2020
AU-2021380315-A1 Stable salt and crystal forms of 2-(3-({1-(2-(dimethylamino)ethyl)-2-(2,2-dimethylpropyl)-1h-1,3-benzodiazol-5-yl}sulfonyl)azetidin-1-yl)ethan-1-ol Active 12-Nov-2020
AU-2021380315-B2 Stable salt and crystal forms of 2-(3-({1-(2-(dimethylamino)ethyl)-2-(2,2-dimethylpropyl)-1h-1,3-benzodiazol-5-yl}sulfonyl)azetidin-1-yl)ethan-1-ol Active 12-Nov-2020 C07D403/12
To view AskAt’s complete patent history, request access »

AskAt Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

AskAt Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
RaQualia Pharma Corporation Minority
Shizuoka Capital Corporate Venture Capital Minority
To view AskAt’s complete investors history, request access »

Ready to get started?

Request a free trial

AskAt FAQs

  • When was AskAt founded?

    AskAt was founded in 2013.

  • Where is AskAt headquartered?

    AskAt is headquartered in Nagoya, Japan.

  • What is the size of AskAt?

    AskAt has 10 total employees.

  • What industry is AskAt in?

    AskAt’s primary industry is Drug Discovery.

  • Is AskAt a private or public company?

    AskAt is a Private company.

  • What is AskAt’s current revenue?

    The current revenue for AskAt is .

  • How much funding has AskAt raised over time?

    AskAt has raised $2.65M.

  • Who are AskAt’s investors?

    RaQualia Pharma and Shizuoka Capital have invested in AskAt.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process